CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 95 filers reported holding CRINETICS PHARMACEUTICALS IN in Q3 2021. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $192,626 | +168.1% | 6,477 | +62.5% | 0.01% | +166.7% |
| Q2 2023 | $71,846 | +12.2% | 3,987 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $64,031 | -19.3% | 3,987 | 0.0% | 0.00% | 0.0% |
| Q4 2022 | $79,341 | +1.7% | 3,987 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $78,000 | +5.4% | 3,987 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $74,000 | -5.1% | 3,987 | +11.9% | 0.00% | 0.0% |
| Q1 2022 | $78,000 | -22.8% | 3,562 | 0.0% | 0.00% | 0.0% |
| Q4 2021 | $101,000 | +68.3% | 3,562 | +24.5% | 0.00% | +50.0% |
| Q3 2021 | $60,000 | +11.1% | 2,860 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $54,000 | +45.9% | 2,860 | +19.7% | 0.00% | +100.0% |
| Q1 2021 | $37,000 | +8.8% | 2,390 | 0.0% | 0.00% | -50.0% |
| Q4 2020 | $34,000 | -8.1% | 2,390 | 0.0% | 0.00% | 0.0% |
| Q3 2020 | $37,000 | -11.9% | 2,390 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $42,000 | +200.0% | 2,390 | +151.1% | 0.00% | +100.0% |
| Q1 2020 | $14,000 | -41.7% | 952 | 0.0% | 0.00% | 0.0% |
| Q4 2019 | $24,000 | +71.4% | 952 | 0.0% | 0.00% | 0.0% |
| Q3 2019 | $14,000 | -41.7% | 952 | 0.0% | 0.00% | 0.0% |
| Q2 2019 | $24,000 | +84.6% | 952 | +65.9% | 0.00% | 0.0% |
| Q1 2019 | $13,000 | -23.5% | 574 | 0.0% | 0.00% | 0.0% |
| Q4 2018 | $17,000 | +6.2% | 574 | 0.0% | 0.00% | 0.0% |
| Q3 2018 | $16,000 | – | 574 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 410,360 | $11,658,000 | 6.24% |
| 5AM Venture Management, LLC | 862,286 | $24,498,000 | 4.60% |
| Bain Capital Life Sciences Investors, LLC | 2,029,701 | $57,664,000 | 4.57% |
| Opaleye Management Inc. | 724,400 | $20,580,000 | 4.36% |
| Deep Track Capital, LP | 1,900,000 | $53,979,000 | 3.81% |
| BVF INC/IL | 3,003,879 | $85,340,000 | 3.10% |
| FRAZIER MANAGEMENT LLC | 1,384,293 | $39,328,000 | 3.03% |
| Altium Capital Management LP | 331,000 | $9,404,000 | 2.59% |
| Perceptive Advisors | 10,327,034 | $293,392,000 | 2.26% |
| MPM BioImpact LLC | 379,792 | $10,790,000 | 1.97% |